Hypertrophic Cardiomyopathy clinical trials

Explore recruiting hypertrophic cardiomyopathy clinical trials.

Recruiting hypertrophic cardiomyopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypertrophic Cardiomyopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled and Open-label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Spain, Italy, Ireland

Phase II and Phase III (Integrated) EU CTIS Study details

MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)

Hungary, Finland, Spain, France, Greece, Italy +5 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO)

Poland, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

The use of empagliflozin in patients with hypertrophic cardiomyopathy

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (age 12 years to < 18 years) with Symptomatic Obstructive Hypertrophic Cardiomyopathy (SCOUT-HCM)

Germany, Spain, Italy, Ireland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

Spain, Netherlands, Denmark, France, Belgium, Czechia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hypertrophic Cardiomyopathy trials by city

Hypertrophic Cardiomyopathy in Toronto Hypertrophic Cardiomyopathy in Vancouver Hypertrophic Cardiomyopathy in Montreal Hypertrophic Cardiomyopathy in Calgary Hypertrophic Cardiomyopathy in Edmonton Hypertrophic Cardiomyopathy in Ottawa Hypertrophic Cardiomyopathy in Winnipeg Hypertrophic Cardiomyopathy in Quebec City Hypertrophic Cardiomyopathy in Hamilton Hypertrophic Cardiomyopathy in Kitchener Hypertrophic Cardiomyopathy in London Hypertrophic Cardiomyopathy in Halifax Hypertrophic Cardiomyopathy in New York Hypertrophic Cardiomyopathy in Los Angeles Hypertrophic Cardiomyopathy in Chicago Hypertrophic Cardiomyopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease